Author: ["Samuel J McConkey","William H H Reece","Vasee S Moorthy","Daniel Webster","Susanna Dunachie","Geoff Butcher","Jenni M Vuola","Tom J Blanchard","Philip Gothard","Kate Watkins","Carolyn M Hannan","Simone Everaere","Karen Brown","Kent E Kester","James Cummings","Jackie Williams","D Gray Heppner","Ansar Pathan","Katie Flanagan","Nirmalan Arulanantham","Mark T M Roberts","Michael Roy","Geoffrey L Smith","Joerg Schneider","Tim Peto","Robert E Sinden","Sarah C Gilbert","Adrian V S Hill"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
In animals, effective immune responses against malignancies and against several infectious pathogens, including malaria, are mediated by T cells. Here we show that a heterologous prime-boost vaccination regime of DNA either intramuscularly or epidermally, followed by intradermal recombinant modified vaccinia virus Ankara (MVA), induces high frequencies of interferon (IFN)-γ-secreting, antigen-specific T-cell responses in humans to a pre-erythrocytic malaria antigen, thrombospondin-related adhesion protein (TRAP). These responses are five- to tenfold higher than the T-cell responses induced by the DNA vaccine or recombinant MVA vaccine alone, and produce partial protection manifest as delayed parasitemia after sporozoite challenge with a different strain of Plasmodium falciparum. Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans.Cite this article
McConkey, S., Reece, W., Moorthy, V. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9, 729–735 (2003). https://doi.org/10.1038/nm881 